Non-coding RNA in drug resistance of gastric cancer
- PMID: 31798777
- PMCID: PMC6883183
- DOI: 10.4251/wjgo.v11.i11.957
Non-coding RNA in drug resistance of gastric cancer
Abstract
Gastric cancer (GC) is the third leading cause of cancer-related mortality worldwide. The poorly prognosis and survival of GC are due to diagnose in an advanced, non-curable stage and with a limited response to chemotherapy. The acquisition of drug resistance accounts for the majority of therapy failure of chemotherapy in GC patients. Although the mechanisms of anticancer drug resistance have been broadly studied, the regulation of these mechanisms has not been completely understood. Accumulating evidence has recently highlighted the role of non-coding RNAs (ncRNAs), including long non-coding RNAs and microRNAs, in the development and maintenance of drug resistance due to their regulatory features in specific genes involved in the chemoresistant phenotype of GC. We review the literature on ncRNAs in drug resistance of GC. This review summarizes the current knowledge about the ncRNAs' characteristics, their regulation of the genes involved in chemoresistance and their potential as targeted therapies for personalized treatment in resistant GC.
Keywords: Drug resistance; Gastric cancer; Long non-coding RNAs; MicroRNAs; Multidrug resistance; Non-coding RNAs.
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors declare that there is no conflict of interests regarding the publication of this paper.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous